This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A 30-something presented with chest pain, palpitations, and SOB. He has had similar symptoms for 4 years, but has never been evaluated. Here is his presenting ECG, which was sent to me real time, along with the 2nd ECG below: Regular Narrow Fast without P-waves. PSVT. It is very difficult to tell if this is: 1) AVNRT or 2) orthodromic AVRT (Orthodromic AVRT = WPW with orthograde conduction down the AV node and retrograde up an accessory pathway) See Ken Grauer's discussion below in differentiati
According to a recent study, high levels of sedentary behavior and physical inactivity from childhood strain the heart in adolescence. High cardiac workload predicts heart failure and other heart diseases. In light of the findings, increasing moderate and vigorous physical activity from childhood onwards is particularly important in preventing heart diseases.
milla1cf Tue, 05/07/2024 - 12:54 May 7, 2024 — HonorHealth Research Institute ’s David G. Rizik , M.D., narrates and is a co-producer of a documentary focused on radiation and orthopedic injuries suffered by doctors and nurses who work in cardiac catheterization laboratories where they apply the very latest non-surgical technologies to treat the world’s leading cause of death, heart disease.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
(MedPage Today) -- The Apple Watch atrial fibrillation feature got added to FDA's list of qualified devices for use in clinical studies. (Mashable) The SGLT2 inhibitor ertugliflozin (Steglatro) showed promise for the reduction of functional mitral.
An example of white matter hyperintensities (WMHs) on a FLAIR MRI scan in an older adult. FLAIR MRI is a technique that is particularly good at detecting fluid in the brain. It helps researchers see areas of the brain that might be damaged by making the cerebrospinal fluid appear dark while the surrounding tissue remains light and detailed. This contrast makes it easier to identify abnormalities or injuries; WMHs appear as bright, patchy regions in the brain tissue.
Pain relief and healthcare satisfaction were significantly increased in patients who were educated about their fibromyalgia and received care from a knowledgeable clinician who gave them information and guidance.
Pain relief and healthcare satisfaction were significantly increased in patients who were educated about their fibromyalgia and received care from a knowledgeable clinician who gave them information and guidance.
milla1cf Tue, 05/07/2024 - 12:59 May 7, 2024 — RapidAI , the global leader in developing clinically deep Artificial Intelligence ( AI ) and technology workflow solutions to combat life-threatening neurovascular, cardiac, and vascular diseases, today announced that the Food and Drug Administration ( FDA ) has granted 510(k) clearance for its AngioFlow by RapidAI solution.
Researchers have discovered a protein marker to help identify cells able to repopulate in patients with damaged blood vessels. Their findings could lead to new therapies for people with endothelial dysfunction, a type of disorder that contributes to coronary artery disease that may occlude with plaque and lack ability to carry sufficient blood into the heart tissue causing a heart attack.
Experts discuss challenges in integrating gene therapy and port delivery systems early in treating common retinal diseases while emphasizing historical challenges and safety considerations.
This randomized clinical trial investigates if patients with high bleeding risk and a history of myocardial infarction (MI) would benefit from complete vs culprit-only revascularization.
Several abstracts featuring data from NCDR’s family of registries – including the CathPCI Registry, the SVS VQI Registry (formerly known as the PVI Registry) and STS/ACC TVT Registry – were presented at SCAI 2024, held May 2-4 in Long Beach, CA.
Proteinuria < 1 g/d is the current treatment target, but findings suggest patients with uACR between 0.3 and 1.0 g/g face a substantial risk of adverse kidney outcomes.
Background The treatment of pulmonary hypertension (PH) has improved rapidly in recent decades. There is increasing evidence to support the role of early intervention and treatment in affecting clinical outcomes in PH. Objectives To assess treatment effects before and after the escalation of specific PH treatments using continuous heart monitoring with a Reveal LINQ loop recorder.
Echocardiogram is an image of the heart using ultrasound. An ultrasound beam is transmitted into the body using a device known as transducer. The echo received from the body is processed by the computer in the machine to give an image of the heart. Transesophageal echocardiogram or TEE test, is obtained by introducing a special type of transducer, also called a TEE probe, through the throat into the food pipe (esophagus) and stomach.
The impact of chest compression (CC) pause duration on survival outcomes in pediatric in-hospital cardiac arrests remains unclear, despite the American Heart Association’s recommendation to limit pauses to less than 10 seconds for children without solid evidence. A recent study published in Circulation explored whether longer maximum CC pause durations correlate with poorer survival and neurological outcomes.
The following are key points to remember about a clinical guideline from the American College of Physicians (ACP) on newer pharmacologic treatments in adults with type 2 diabetes.
These data highlight the elements known to impact patient-reported outcomes among those with psoriasis and successful clinician-reported outcomes following biologic use.
Implantable cardioverter defibrillator (ICD) prevents sudden cardiac death (SCD) in patients with ischemic cardiomyopathy (ICM). Catheter ablation has been shown to effectively reduce ventricular tachycardia (VT) recurrence, yet its efficacy in patients without an ICD implantation remains uncertain.
Catheter ablation is one of the most effective rhythm-control strategies for atrial fibrillation (AF). Conventional catheter ablation is performed using thermo-energy sources via either radiofrequency that burns cardiac tissue through heat or cryoablation that freezes tissue under ultralow temperature.
Hydroxychloroquine (HCQ) and chloroquine (CQ) are foundational treatments for several systemic autoimmune rheumatic diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Concerns regarding the risk of cardiac arrhythmia and death have been raised, yet the burden of HCQ and CQ-related cardiac toxicities remains unclear.
Daniela Ferrara, MD, PhD described the key takeaways from the machine learning model's performance in predicting outcomes for various treatment durations of faricimab in DME.
During this interview segment, Browning highlighted the impact of a future FDA acceptance of tapinarof for atopic dermatitis as well as the next milestones in regulatory approval.
Women and black patients were less frequently treated with minimally invasive therapy compared to men or non-Black patients, according to new data from the REAL-PE analysis which investigated catheter-based pulmonary embolism (PE) treatment. Late-breaking results from the study, for which Sahil A. Parikh, MD, Associate Professor of Medicine, Columbia University Irving Medical Center was lead author, were shared during the recently-held Society for Cardiovascular Angiography & Interventions (SCA
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
131 
Let's personalize your content